Drug

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches
DiabetesNovo Nordisk

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches

According to a notice from the UK Department of Health and Social Care (DHSC), Novo Nordisk A/S (NYSE: NVO) will withdraw all forms of Levemir (insulin detemir) by the end…

GeneScience Pharmaceuticals' 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT

GeneScience Pharmaceuticals’ 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT

Daiichi Sankyo's DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Daiichi Sankyo’s DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sino Biopharm's TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers
Chia Tai Tianqing PharmaceuticalClinical trial approval / initiation

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

ADC / XDCCancer

Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers

Clinical trial approval / initiationHengrui Pharmaceuticals

Hengrui’s SHR-2524 Wins NMPA Phase I Approval – Novel Subcutaneous Formulation Plus Bevacizumab Targets First-Line Liver Cancer

Boehringer Ingelheim's Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis
Market launch

Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai – First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis

Show More